Categorynews

FORMA Therapeutics Announces New Executive Leadership to Execute Next Phase of Growth for Company

September 24, 2019 Off By BusinessWire

WATERTOWN, Mass.–(BUSINESS WIRE)–FORMA Therapeutics, Inc. (“Company”) announced today the appointments of Todd Shegog as Senior Vice President, Chief Financial Officer and Jeannette Potts, Ph.D., J.D. as Senior Vice President, General Counsel and Corporate Secretary, and recognized the recent promotions of Patrick Kelly, M.D. to Senior Vice President, Chief Medical Officer and Mary Wadlinger to Senior Vice President, Corporate Affairs and Chief Human Resources Officer. The Company also announced the appointments of Scott Boyle, Ph.D. as Vice President, Business and Corporate Development and Brian Lesser as Vice President, Therapeutic Head.

“This new leadership team will allow us to rapidly advance FORMA’s efforts focused on rare hematology and oncology diseases with significant unmet needs,” said Frank Lee, CEO of FORMA. “I am pleased to welcome these talented leaders and look forward to working together to achieve our goal of delivering transformative medicines to patients.”

Todd Shegog joins FORMA with more than 25 years of financial experience in the biotechnology and pharmaceutical industries. He most recently served as Chief Financial Officer for publicly-traded Synlogic where he directed the company’s financial strategy and management as well as facilities and information systems. Prior to Synlogic, Todd served as Senior Vice President and Chief Financial Officer at Forum Pharmaceuticals, where he was responsible for finance, operations and information systems.

Jeannette Potts joins FORMA following 23 years as in-house counsel at Takeda Pharmaceuticals and Millennium Pharmaceuticals. She most recently served as Vice President and Head Counsel, Research & Development at Takeda where she was the primary senior legal advisor and strategic partner to its global R&D organization leading a team of 35 legal professionals.

Pat Kelly joined FORMA in 2016 and has led translational clinical activities for FORMA’s portfolio of small molecule therapeutics. In his new role, Pat will oversee development. Mary Wadlinger joined FORMA in 2014 as Senior Vice President, Human Resources and has played an integral part in FORMA’s transformation. In her new role, Mary will now also oversee the newly created functions of communications and patient advocacy.

Scott Boyle brings to FORMA years of strategic and operational experience spanning corporate and business development, new product development, policy and research. He most recently served as a principal at the Boston Consulting Group (BCG) where he was responsible for developing strategies for clients in oncology and precision medicine. Prior to BCG, Scott served as Vice President, Business Development at Caris Life Sciences where he was responsible for commercializing Caris’ molecular data assets, proprietary discovery platform and laboratory capabilities into precision medicine services, and products and collaborations with biopharma and data companies.

Brian Lesser brings over 20 years of pharmaceutical sales and marketing experience spanning multiple therapeutic areas and molecule lifecycle phases. Brian joins FORMA after more than a decade at Genentech, most recently as the Global Lifecycle Leader of Xofluza™, a first-in-class and best-in-disease antiviral for influenza, where he led its global development and commercialization. His former roles at Genentech include National Sales Director (Transplant), Director of Marketing (Breast Cancer), Director of Marketing (Tamiflu), and Brand Director (Transplant).

About FORMA Therapeutics

FORMA Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of transformative medicines that will make a difference for patients in need. A fully-integrated biopharmaceutical company, FORMA’s validated, proprietary R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates with best-in-class or first-in-class potential. FORMA has delivered high-value clinical candidates to its partners and generated a broad proprietary portfolio of programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic, and metabolic indications. For more information, please visit the company website at www.formatherapeutics.com.

Join the conversation on Twitter @FORMAInc and LinkedIn